Company intelligence / Profile preview

Koutif Therapeutics

Beachwood, Ohio, United Stateskoutiftherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Koutif Therapeutics develops first-in-class small molecule inhibitors targeting Fbxo3 to modulate inflammation by promoting degradation of pro-inflammatory proteins. Their lead compound, KT‑1002, received FDA IND clearance in early 2019 to begin Phase 1 trials for IBD. The company’s technology originates from discoveries at University of Pittsburgh and VA Medical Center. No published clinical results yet; Phase 1 will assess safety and pharmacokinetics.

Therapeutic areas: Gastroenterology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BC1261

Unknown

Partnerships

Exclusive IP license from University of Pittsburgh and U.S. Department of Veterans Affairs

Beyond the preview

Go deeper on Koutif Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Koutif Therapeutics.

Explore the full profile